Elevation Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.67M Buy
1,388
+844
+155% +$862K 0.5% 36
2026
Q1
$501K Sell
544
-19
-3% -$19.3K 0.18% 76
2025
Q4
$605K Sell
563
-45
-7% -$43K 0.21% 64
2025
Q3
$464K Buy
608
+46
+8% +$34.2K 0.17% 79
2025
Q2
$438K Sell
562
-77
-12% -$59.8K 0.17% 77
2025
Q1
$528K Sell
639
-11
-2% -$9.15K 0.23% 64
2024
Q4
$502K Hold
650
0.21% 67
2024
Q3
$576K Hold
650
0.25% 62
2024
Q2
$588K Hold
650
0.28% 57
2024
Q1
$506K Sell
650
-150
-19% -$107K 0.25% 68
2023
Q4
$430K Buy
+800
New +$467K 0.26% 69

Other funds holding LLY

Elevation Wealth Partners's LLY Position: Q2 2026 in Review

Elevation Wealth Partners increased its Eli Lilly (LLY) stake by 155% in Q2 2026, buying an estimated $862K and bringing the position to 1,388 shares worth $1.67M. The position accounts for 0.5% of the portfolio, ranked #36.

Elevation Wealth Partners first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,640 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Elevation Wealth Partners held 1,388 shares of Eli Lilly worth $1.67M as of Q2 2026.
  • Elevation Wealth Partners bought 844 Eli Lilly shares in Q2 2026, an estimated $862K.
  • Eli Lilly made up 0.5% of Elevation Wealth Partners's portfolio in Q2 2026, its #36 holding.
  • Elevation Wealth Partners first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,640 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.